Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The HealthCare Segment at Bayer (BAYRY - Analyst Report) has been the key revenue generator at the company for the last few years. Nexavar is one of the leading revenue drivers at the segment. Nexavar is approved for liver cancer and advanced kidney cancer in over 100 countries around the globe.

Bayer and partner Onyx Pharmaceuticals Inc., now a wholly owned subsidiary of Amgen Inc. (AMGN - Analyst Report), submitted a marketing authorization application to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Nexavar for the treatment of locally advanced or metastatic thyroid cancer. Nexavar enjoys orphan drug designation in Japan for this indication.

In Jun 2013, Bayer also submitted regulatory applications in the U.S. and EU for Nexavar for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer. The regulatory filings were based on positive results from the phase III DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer) trial. Nexavar is under priority review for the indication in the U.S.

Results from the study revealed a significant increase in progression-free survival (PFS) of patients treated with Nexavar compared to placebo. Data revealed a 41% reduction in the risk of disease progression or death in patients receiving Nexavar compared to patients under placebo.

Bayer reported Nexavar sales of €200 million in the second quarter of 2013, up 2.6% year over year. Further label expansion will boost Nexavar’s sales. However, the oncology market is extremely competitive given the presence of companies like Roche (RHHBY - Analyst Report).

Bayer, a large-cap pharma company, presently carries a Zacks Rank #4 (Sell). Other large-cap pharma stocks such as Roche and Allergan Inc. (AGN - Analyst Report) currently appear to be more attractive. While Roche carries a Zacks Rank #1 (Strong Buy), Allergan carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%